What You Should Know: – Virta Health, a San Francisco, CA-based company raises $133M led by , to scale its virtual metabolic clinic and approach to reversing chronic metabolic conditions (type 2 diabetes, prediabetes, and obesity) to the masses led by Tiger Global. – The… Read More »Virta Health Raises $133M to Expand Type 2 Diabetes Reversal Platform
After announcing plans to go public, prescription digital therapeutics (DTx) firm Better Therapeutics has begun a “real world” study to test whether its BT-001 prescription cognitive behavioural therapy tool could change behaviours that are the root cause of type 2 diabetes. The company has begun… Read More »Better Therapeutics begins ‘real world’ study of digital diabetes therapy
Digital health startup Better Therapeutics plans to go public through a SPAC merger that would value it at $187 million. The company is currently running a pivotal study to see if its app-based program could be used as a treatment for type 2 diabetes.
What You Should Know: – Blue Shield of California is enhancing its popular Wellvolution program by adding two new services that provide personalized care and nutrition support for members living with or at risk for Type 2 diabetes. – Wellvolution is a digitally based lifestyle… Read More »Blue Shield of CA Expands into Digital Health with Wellvolution Expansion
Shots: The companies expanded the collaboration to improve health for people with T2D. The agreement integrates the Dexcom G6 CGM system and Welldoc’s BlueStar digital health solution as a single platform offering The focus of the agreement is to empower users to take control of… Read More »Welldoc Expands their Partnership with Dexcom to Offer Type 2 Diabetes Management Solution
Shots: The US FDA has issued refusal to file a letter covering the label expansion application for semaglutide (2.0mg/qw) for T2D, which was submitted on Jan 20, 2021 The US FDA has requested additional information including data relating to new manufacturing site Novo Nordisk plans… Read More »Novo Nordisk Receives the US FDA’s Refusal to File Letter for Semaglutide to Treat T2D
Shots: The P-III SURPASS-2 trial involves assessing Tirzepatide (5/10/15mg) vs Semaglutide (1mg) in 1,879 patients in a ratio (1:1:1:1) with T2D inadequately controlled with ≥1500 mg/day metformin alone for 40wks. Results: A1C reduction: (-2.09% /-2.37%/-2.46% vs- 1.86%); Weight reduction: (-7.8/-10.3/-12.4kg vs -6.2 kg); patients achieving… Read More »Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes
Athar Siddiqui: Global Strategy Lead, Digital Connected Solutions – Ascensia Diabetes Care “Information technology and business are becoming inextricably interwoven. I don’t think anybody can talk meaningfully about one without the talking about the other” – Bill Gates wrote this in 1999 and, nowadays, the… Read More »Data-Driven Future: Impact of Machine Learning on Diabetes Management
Shots: The P-lll SURPASS-3 study involves assessing Tirzepatide (5/10/15 mg) vs titrated insulin degludec in 1444 participants in a ratio (1:1:1:1) with T2D treated with metformin with or without an SGLT-2 inhibitor for 52wks. The P-lll SURPASS-5 study involves assessing Tirzepatide (5/10/15 mg) vs PBO… Read More »Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes
What You Should Know: – Verily’s Onduo, known for its tech-based solution for virtual diabetes management, is launching a new multi-condition platform that matches the right care to the right consumer at the right time. The expanded virtual care platform is designed to support patients managing type 2… Read More »Verily’s Onduo Virtual Care Solution Expands to Multi-Condition Platform
What You Should Know: – DarioHealth, a Livongo competitor acquires musculoskeletal startup Upright for $31 million to expand their chronic condition management capabilities focused on driving behavior change rather than treating the acute problem. This move will more than double revenue and create one of… Read More »DarioHealth Acquires Musculoskeletal Solution Upright for $31M
What You Should Know: – Teladoc Health and Dexcom announced an expanded partnership on a new offering measures the impact of continuous glucose monitoring and real-time health recommendations for people with Type 2 diabetes at no cost. Teladoc Health, Inc., the first and only comprehensive… Read More »Teladoc Health, Dexcom Offers CGM-Powered insights to People with Type 2 Diabetes
Shots: The P-lll SURPASS-1 study involves assessing Tirzepatide as monothx. (5/10/15 mg) vs PBO in 478 patients in the ratio of (1:1:1:1) with T2D inadequately controlled with diet and exercise alone Results: A1C reduction: (-1.75% /-1.71%/-1.69% vs- 0.09%); Weight reduction: 6.3/7.0/7.8kg vs 1.0 kg; percentage… Read More »Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes
What You Should Know: – Virta just closed a $65 Series D round, to scale its virtual clinic and approach to reversing chronic metabolic conditions (T2D, prediabetes, and obesity) to the masses. – The financing, led by Sequoia Capital Global Equities, also hurdles Virta well… Read More »Virta Health Reaches Unicorn Status After Raising $65M to Reverse Type 2 Diabetes
Shots: The P-III FIDELIO-DKD study in CKD and T2D enrolled over 13,000 patients with early kidney damage and more advanced stages of kidney disease. The data were presented at the ASN Kidney Week 2020 and published in the NEJM based on which Bayer submitted finerenone… Read More »Bayer’s Finerenone Demonstrates Positive Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
What You Should Know: – Omada’s diabetes prevention program will be available to Intermountain’s at-risk patient population as part of a limited engagement in 2020 and 2021. – Omada’s diabetes prevention program is personalized to meet each participant’s unique needs as they evolve, ranging from… Read More »Intermountain Adds Omada’s Diabetes Prevention Program to At-Risk Patients
Bayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication of data from the phase 3 FIDELIO-DKD trial. Bayer teased the top-line result from the study back in July, providing the first clue that its sizeable investment… Read More »Bayer data for kidney disease hope finerenone sets up filings
What You Should Know: – Today, Blue Cross and Blue Shield of North Carolina partners with Carrot Inc. and Virta Health to help address two of the largest ongoing health issues facing Americans today – smoking and type 2 diabetes. – Virta and Carrot’s programs… Read More »Blue Cross NC Launches No-Cost Virtual Programs to Quit Smoking and Reverse Diabetes
Date: October 19, 2020 Issue #: 1609 Summary: The FDA has approved two additional doses (3 mg and 4.5 mg) of the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide (Trulicity – Lilly) for treatment of type 2 diabetes in adults. Dulaglutide has been available in 0.75-… Read More »Two New Doses of Dulaglutide (Trulicity) for Diabetes
What You Should Know: – Virta is expanding its suite of treatment options to include prediabetes reversal, obesity reversal, and type 2 diabetes management. – By making this crucial expansion, Virta can scale its treatment to support the tens of millions of additional patients with… Read More »Virta Expands Offerings to Treat New Group of Chronic Illnesses
What You Should Know: – NIH awards funding for Rare and Atypical Diabetes Network, or RADIANT that will seek to discover the cause of several unusual forms of diabetes. – RADIANT plans to screen about 2,000 people with unknown or atypical forms of diabetes that… Read More »NIH Funds First Nationwide Rare and Atypical Diabetes Network
Date: October 19, 2020 Issue #: 1609 Summary: The FDA has approved insulin lispro-aabc (Lyumjev – Lilly), a faster-acting formulation of insulin lispro (Humalog), for treatment of type 1 and type 2 diabetes in adults. Fiasp, a faster-acting formulation of insulin aspart (Novolog), was approved… Read More »Lyumjev – A New Insulin Lispro for Diabetes
What You Should Know: – DreaMed Diabetes, the developer of personalized, AI-based diabetes management solutions, will participate in a clinical study, led by Jaeb Center for Health Research Foundation, to evaluate the efficacy of virtual treatment for diabetes patients. The research is funded by a… Read More »$5M Research Grant Launches to Evaluate Efficacy of Virtual Diabetes Care
– Lemonaid Health, a direct to consumer telehealth company raises $33M in Series B funding to expand the company’s medical team and number of services being offered to patients. – To date, the company has treated more than a million patients online for a variety… Read More »Lemonaid Health Raises $33M to Expand On-Demand Consumer Telehealth Platform